Navigation Links
Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011
Date:4/29/2011

MISSISSAUGA, Ontario, April 29, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Monday, May 9, 2011 at 10:00 a.m. ET (7:00 a.m. PT) to discuss results for the 2011 first quarter.

The dial-in number to participate on this call is (877) 295-5743, confirmation code 63195016.  International callers should dial (973) 200-3961, confirmation code 63195016. A replay will be available approximately two hours following the conclusion of the conference call to Monday, May 16, 2011, and can be accessed by dialing (800) 642-1687 or (706) 645-9291, confirmation code 63195016.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant can be found at www.valeant.com.

(Logo:  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
2. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
3. Regulatory Update - GSK and Valeant Respond to FDA on ezogabine
4. Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors
5. Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
6. Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
7. Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States
8. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
9. GSK and Valeant Receive European Authorisation for Trobalt (retigabine)
10. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
11. Valeant Pharmaceuticals Completes Acquisition of PharmaSwiss S.A.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 27, 2017  Market Research presents an all-encompassing and one ... market titled ,Medical Fiber Optics Market: Global Industry Analysis and ... globally across the five key regions of North ... Europe , APAC and MEA which influence the ... optics market over the forecast period. In this report, Persistence ...
(Date:2/28/2017)... TRIANGLE PARK, N.C. , Feb. 28, 2017 ... that Martine Rothblatt , Ph.D., Chairman and Chief Executive ... on the company,s business at the Cowen and Company 37 ... Massachusetts . The presentation will take place ... and can be accessed via a live webcast on the ...
(Date:2/28/2017)... 27, 2017  Clarivate Analytics marks the passing of one if its ... contributions to information science in the service of scientific and scholarly research. ... an indexing system that revolutionized the way researchers work with the literature, ... Continue Reading ... ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... 27, 2017 , ... Much attention has been paid to the problem of ... opioid painkillers has fallen short. From 1999 until 2010, fatal overdoses from prescription pain ... overdoses in male populations.(1) , The proportion of women using illicit drugs is also ...
(Date:2/27/2017)... ... 2017 , ... Elisa Guajardo Carothers is not your typical author. She went from working as ... Now, she writes about God, when she isn’t swimming as a performing mermaid. , Her ... BS! (Before Satan),” she offers a comedic look at the dysfunctions of God’s family, before ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... on laser diffraction analysis as a tool to characterize particle size distributions in ... to obtain improved results and novel scientific findings. It describes methods of optimized ...
(Date:2/27/2017)... POUGHKEEPSIE, N. Y. (PRWEB) , ... February 27, 2017 , ... ... Society ( ILADS ) has disclosed that despite scientific studies, the Center for Disease ... of chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is ... team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in ...
Breaking Medicine News(10 mins):